Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
- Resource Type
- Article
- Authors
- Meng, Xiangrui; Wu, Tao; Hong, Yonggui; Fan, Qingxia; Ren, Zhonghai; Guo, Yanzhen; Yang, Xiuli; Shi, Pei; Yang, Jiamei; Yin, Xianzhe; Luo, Zhiquan; Xia, Jin; Zhou, Yue; Xu, Mengli; Liu, Enjie; Jiang, Guozhong; Li, Shenglei; Zhao, Feng; Ma, Chi; Ma, Chuanxiang; Hou, Zhiguo; Li, Jing; Wang, Junsheng; Wang, Feng
- Source
- In The Lancet Gastroenterology & Hepatology March 2022 7(3):245-253
- Subject
- Primary Research
Articles
- Language
- ISSN
- 2468-1253